| SIGA Technologies, Inc. (SIGA) Q1 2025 Earnings Call Transcript |
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Dan Luckshire - Executive Vice President & Chief Financial Officer Conference Call Participants Jyoti Prakash - Edison Group Operator Good afternoon. Welcome to SIGA Technologies business update call. |
seekingalpha.com |
2025-05-08 23:16:01 |
Czytaj oryginał (ang.) |
| SIGA Reports Financial Results for Three Months Ended March 31, 2025 |
Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. “SIGA has carried its momentum from 2024 into 2025, achieving steady progress on its key initiatives,” stated Diem Nguyen, Chief Executive Officer. |
globenewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for Investors |
In the most recent trading session, Siga Technologies Inc. (SIGA) closed at $5.43, indicating a -1.63% shift from the previous trading day. |
zacks.com |
2025-05-01 22:50:39 |
Czytaj oryginał (ang.) |
| SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results |
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 8, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. |
globenewswire.com |
2025-05-01 11:30:00 |
Czytaj oryginał (ang.) |
| Here's Why Siga Technologies Inc. (SIGA) Gained But Lagged the Market Today |
Siga Technologies Inc. (SIGA) reachead $6.51 at the closing of the latest trading day, reflecting a +0.39% change compared to its last close. |
zacks.com |
2025-04-25 22:50:34 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Outperforms Broader Market: What You Need to Know |
The latest trading day saw Siga Technologies Inc. (SIGA) settling at $6.25, representing a +1.96% change from its previous close. |
zacks.com |
2025-04-23 22:55:37 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Falls More Steeply Than Broader Market: What Investors Need to Know |
In the latest trading session, Siga Technologies Inc. (SIGA) closed at $6.04, marking a -1.79% move from the previous day. |
zacks.com |
2025-04-15 22:55:35 |
Czytaj oryginał (ang.) |
| SIGA Declares Special Cash Dividend of $0.60 Per Share |
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. This represents the fourth straight year of a special cash dividend. The amount of the dividend declared is consistent with the level of the dividend declared in March 2024. The dividend is payable on May 15, 2025, to shareholders of record at the close of business on April 29, 2025. |
globenewswire.com |
2025-04-08 11:30:00 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Declines More Than Market: Some Information for Investors |
In the most recent trading session, Siga Technologies Inc. (SIGA) closed at $5.32, indicating a -1.3% shift from the previous trading day. |
zacks.com |
2025-04-07 22:55:48 |
Czytaj oryginał (ang.) |
| SIGA Technologies: Asymmetric Upside, If 2025 Goes Right |
SIGA Technologies' strong cash position and high FCF margins provide a valuation floor, but growth is limited without new catalysts, supporting a "speculative Buy" rating. Key 2025 catalysts include potential PEP approval and a new BARDA contract, which could significantly boost SIGA's valuation. SIGA's reliance on unpredictable orthopoxvirus outbreaks and government funding poses risks, making it suitable for a barbell portfolio with speculative investment. |
seekingalpha.com |
2025-04-07 07:02:37 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Stock Slides as Market Rises: Facts to Know Before You Trade |
In the latest trading session, Siga Technologies Inc. (SIGA) closed at $5.74, marking a -0.35% move from the previous day. |
zacks.com |
2025-03-19 20:50:23 |
Czytaj oryginał (ang.) |
| SIGA Appoints Retired General John M. Keane to its Board of Directors |
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army General John “Jack” Keane to its Board of Directors, effective immediately. General Keane, a retired four-star general, completed 37 years of public service in December 2003, culminating with his appointment as acting Chief of Staff and Vice Chief of Staff of the U.S. Army from 1999 to 2003. |
globenewswire.com |
2025-03-18 09:30:00 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Rises Higher Than Market: Key Facts |
In the latest trading session, Siga Technologies Inc. (SIGA) closed at $5.63, marking a +0.9% move from the previous day. |
zacks.com |
2025-03-17 20:55:20 |
Czytaj oryginał (ang.) |
| SIGA Technologies, Inc. (SIGA) Q4 2024 Earnings Call Transcript |
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Dan Luckshire - Executive Vice President and Chief Financial Officer Conference Call Participants Jyoti Prakash - Edison Group Brian Adams - Carter, Terry & Company Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements majoring this call are based on management's current expectations and observations, and are subject to risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. |
seekingalpha.com |
2025-03-11 22:55:49 |
Czytaj oryginał (ang.) |
| SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024 |
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2024. |
globenewswire.com |
2025-03-11 18:05:00 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Ascends While Market Falls: Some Facts to Note |
The latest trading day saw Siga Technologies Inc. (SIGA) settling at $5.43, representing a +0.74% change from its previous close. |
zacks.com |
2025-03-04 20:50:28 |
Czytaj oryginał (ang.) |
| SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results |
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 11, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. |
globenewswire.com |
2025-03-04 09:30:00 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Increases Despite Market Slip: Here's What You Need to Know |
The latest trading day saw Siga Technologies Inc. (SIGA) settling at $6.12, representing a +1.32% change from its previous close. |
zacks.com |
2025-02-20 20:50:35 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Rises Higher Than Market: Key Facts |
The latest trading day saw Siga Technologies Inc. (SIGA) settling at $6.04, representing a +0.83% change from its previous close. |
zacks.com |
2025-02-19 20:51:14 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Stock Drops Despite Market Gains: Important Facts to Note |
In the closing of the recent trading day, Siga Technologies Inc. (SIGA) stood at $6.03, denoting a -0.66% change from the preceding trading day. |
zacks.com |
2025-02-11 20:51:24 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why |
The latest trading day saw Siga Technologies Inc. (SIGA) settling at $5.83, representing a +0.87% change from its previous close. |
zacks.com |
2025-02-04 20:51:16 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Registers a Bigger Fall Than the Market: Important Facts to Note |
In the closing of the recent trading day, Siga Technologies Inc. (SIGA) stood at $6.34, denoting a -1.71% change from the preceding trading day. |
zacks.com |
2025-01-27 20:50:22 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Surpasses Market Returns: Some Facts Worth Knowing |
In the most recent trading session, Siga Technologies Inc. (SIGA) closed at $6.47, indicating a +1.25% shift from the previous trading day. |
zacks.com |
2025-01-23 20:56:25 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Stock Dips While Market Gains: Key Facts |
Siga Technologies Inc. (SIGA) closed the most recent trading day at $6.23, moving -0.24% from the previous trading session. |
zacks.com |
2025-01-17 20:50:33 |
Czytaj oryginał (ang.) |
| Siga Technologies Inc. (SIGA) Advances But Underperforms Market: Key Facts |
The latest trading day saw Siga Technologies Inc. (SIGA) settling at $6.35, representing a +0.32% change from its previous close. |
zacks.com |
2025-01-15 20:55:20 |
Czytaj oryginał (ang.) |
| TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses |
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirimat 200 mg capsules), marketed as TPOXX in the United States, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg. TEPOXX is the first antiviral therapy approved by the Pharmaceuticals and Medical Devices Agency (PMDA), in collaboration with the Japan Ministry of Health, Labour and Welfare, for the treatment of orthopoxviruses. |
globenewswire.com |
2025-01-02 09:30:00 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Siga Technologies (SIGA) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-25 12:41:13 |
Czytaj oryginał (ang.) |
| Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year? |
Here is how Siga Technologies Inc. (SIGA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year. |
zacks.com |
2024-12-11 12:40:15 |
Czytaj oryginał (ang.) |
| Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced |
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analysis of the Study of Tecovirimat for Human Mpox Virus (STOMP) clinical trial (NCT05534984). NIAID reported that SIGA's tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade II mpox. Based on this and additional analyses, the study Data Safety and Monitoring Board (DSMB) recommended to stop enrolling patients in the randomized arms of the study. NIAID accepted this recommendation and subsequently decided to take a similar action in the open label arm of this study, which included severe and at-risk of developing severe disease patients. Data analysis is not yet complete for primary endpoint subgroups and detailed secondary and exploratory endpoints. |
globenewswire.com |
2024-12-10 18:00:00 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Siga Technologies (SIGA) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-09 12:46:32 |
Czytaj oryginał (ang.) |
| Siga Technologies (SIGA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now |
Siga Technologies (SIGA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
zacks.com |
2024-12-05 12:55:17 |
Czytaj oryginał (ang.) |
| SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook |
SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga's long-term outlook. Emergent BioSolutions Inc.'s diversified product portfolio and turnaround strategy under new CEO Joseph Papa provides an optimistic long-term outlook. Siga's financial stability is threatened by potential policy changes driven by the new U.S. government and TPOXX's uncertain efficacy against mpox. |
seekingalpha.com |
2024-12-02 19:49:22 |
Czytaj oryginał (ang.) |
| SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket |
SIGA Technologies' stock has declined 37% since my "speculative buy" recommendation in August, driven by a muted response to the mpox outbreak. The initial recommendation was based on the WHO's mpox emergency declaration and potential increased demand for SIGA's lead asset, tecovirimat. The mpox outbreak has waned, and global authorities' response has been less aggressive, leading to lower-than-expected demand for tecovirimat. |
seekingalpha.com |
2024-11-21 19:01:12 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Siga Technologies (SIGA) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-11-21 12:45:38 |
Czytaj oryginał (ang.) |
| SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman |
SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox. |
globenewswire.com |
2024-11-08 11:18:00 |
Czytaj oryginał (ang.) |
| SIGA Technologies, Inc. (SIGA) Q3 2024 Earnings Call Transcript |
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Diem Nguyen - CEO Dan Luckshire - CFO Conference Call Participants Jyoti Prakash - Edison Group Operator Good afternoon, ladies and gentlemen, and welcome to the SIGA Technologies Third Quarter 2024 Earnings Call. At this time, all lines are in a listen-only mode. |
seekingalpha.com |
2024-11-07 22:55:29 |
Czytaj oryginał (ang.) |
| SIGA Technologies, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SIGA |
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial. |
accesswire.com |
2024-11-07 09:30:00 |
Czytaj oryginał (ang.) |